Bid news and fundraisings have continued to dominate activity on Aim, keeping the junior market's renewed optimism going strong. The international flavour of some of the bigger deals has remained, with
New York-based Keryx Biopharameucticals successfully securing $15 million (£8.3 million) among a bounteous crop.
Expansion into China and a restructuring of US operations form the core of speciality fused materials supplier UCM's reaction to recession, after a £100,000 first half profits slip to £2.4 million pre-tax on turnover £300,000 ahead at £17.8 million, writes Robert Tyerman.
Many chartists claim to have called the bottom of the market and are now forecasting strong gains ahead. But can investors really make money from their pronouncements, or is it just hindsight masquerading as insight? Robert Tyerman reports
Despite the enduring bear market, we are still excited by the potential rewards that ensue when tiny technology stocks make it big. Ben Cobley surveys the current tech crop that are fuelling investors' fascination and greed
London's Small Cap index has now dropped to 1728.95 against 2486.35 a year ago – as a barometer the FTSE 100 has fallen from 5153.9 to 3616.1 over the same period. However, many analysts suggest the smaller shares market has been oversold, with many recruitment ventures, in particular, looking badly undervalued. Generally speaking, these outfits are regarded as bellwethers for the first stirrings of economic recovery.
Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. You can purchase the directory at the pre-order price with a 15% saving (+VAT). Offer valid until 6th October 2015. Order your copy today.
The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info